KM Biologics, a group company of Meiji Seika Pharma, has entered into a technology collaboration with Serum Institute of India (SII) to support the development and manufacturing of a Japanese encephalitis vaccine in India.
- Technology Transfer: The agreement covers the transfer of manufacturing processes and technical expertise for the development and production of a Japanese encephalitis vaccine.
- Manufacturing Development: Under the collaboration, SII will carry out development activities in India for the vaccine currently produced and marketed by KM Biologics, with both parties working together on further development and manufacturing.
- Supply Objective: The collaboration aims to support the establishment of a stable supply of Japanese encephalitis vaccines for use in India’s immunisation programme.
This summary is based on a news report by BioSpectrum Asia.
Image for illustrative purposes only. Source: Canva.
About Ehub365
For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news.
A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.
